Skip to content
Open access

Admission high-sensitivity cardiac troponin T and clinical outcomes after acute ischemic stroke: a retrospective cohort study with exploratory nonlinear analysis

Oct 2026 · Frontiers in Neurology · Vol 17 · 0 citations · 32 references
Medicine

Abstract

Background Elevated high-sensitivity cardiac troponin T (hs-cTnT) is frequently observed in patients with acute ischemic stroke (AIS) and has been associated with adverse outcomes. We aimed to evaluate the association of admission hs-cTnT with 90-day functional outcome and all-cause mortality during follow-up, with particular attention to potential nonlinear risk patterns across the biomarker range. Methods This single-center retrospective cohort study included 564 patients with AIS admitted between January 2022 and October 2024. The primary outcomes were modified Rankin Scale (mRS) at 90 days and long-term all-cause mortality. Multivariable logistic regression was used for poor 90-day functional outcome and Cox proportional hazards models were used for all-cause mortality during follow-up. Restricted cubic spline (RCS) analyses were performed to explore nonlinear dose–response relationships, and segmented regression models were used to estimate exploratory turning points. Results Among 564 patients, 212 (37.6%) had elevated hs-cTnT (>14 ng/L). Elevated hs-cTnT was independently associated with poor 90-day mRS (adjusted OR 1.93, 95% CI, 1.22–3.05; p = 0.005) and all-cause mortality during follow-up (fully adjusted HR 4.12, 95% CI, 2.31–7.48; p < 0.001). During a median follow-up of 17 months (IQR 12–26 months), Kaplan–Meier analysis demonstrated significantly lower overall survival in patients with elevated hs-cTnT (p < 0.001). RCS analysis revealed significant nonlinear associations between hs-cTnT and both endpoints (p < 0.001). Exploratory model-derived turning points were observed at 28.42 ng/L for functional outcome and 31.68 ng/L for mortality; these should be interpreted as exploratory rather than validated clinical cutoffs. Below these values, risk increased more steeply; above them, no statistically significant further increase in risk was observed. Conclusion Admission hs-cTnT was independently associated with 90-day functional outcome and all-cause mortality during follow-up in patients with AIS. The association appeared to be nonlinear, with model-derived turning points at approximately 28–32 ng/L that should be interpreted as exploratory rather than definitive clinical cutoffs. Clinically, hs-cTnT may be useful as a complementary marker for identifying patients at higher risk who may warrant closer neuro-cardiac evaluation, although its incremental predictive value has not been formally assessed.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.